

**Company registration number 529404 (Republic of Ireland)**

**JODEL PHARMACY LIMITED**  
**ABRIDGED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2025**

# JODEL PHARMACY LIMITED

## CONTENTS

---

	<b>Page</b>
Directors' responsibilities statement	1
Directors' declaration	2
Statement of financial position	3 - 4
Notes to the financial statements	5 - 8

---

# JODEL PHARMACY LIMITED

## DIRECTORS' RESPONSIBILITIES STATEMENT

**FOR THE YEAR ENDED 31 MARCH 2025**

---

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.


Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (Generally accepted Accounting Practice in Ireland) issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for that financial year and otherwise comply with the Companies Act 2014.


In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

By order of the board

DocuSigned by:  
  
F82DD634605D450...  
John Shanahan  
**Secretary**

DocuSigned by:  
  
07B02B523E7141A...  
Dolores Shanahan  
**Director**

8 July 2025

# JODEL PHARMACY LIMITED


## DIRECTORS' DECLARATION ON UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

---

In relation to the financial statements which comprise the Statement of Comprehensive Income, Statement of Financial Position and the related notes:

- The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgments underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.
- The directors confirm that they have made available to PKF Brenson Lawlor Limited, all the company's accounting records and provided all the information necessary for the compilation of the financial statements.
- The directors confirm that to the best of their knowledge and belief, the accounting records reflect all transactions of the company for the year ended 31 March 2025.

By order of the board

DocuSigned by:  
  
John Shanahan  
F830D6324695D450...  
**Secretary**

DocuSigned by:  
  
Dolores Shanahan  
07B02B523E7141A...  
**Director**

8 July 2025

**JODEL PHARMACY LIMITED****STATEMENT OF FINANCIAL POSITION****AS AT 31 MARCH 2025**

	Notes	2025		2024	
		€	€	€	€
<b>Fixed assets</b>					
Tangible assets	3		576,115		575,230
<b>Current assets</b>					
Debtors	4	4,052		4,052	
Cash at bank and in hand		3,163		5,838	
			7,215		9,890
<b>Creditors: amounts falling due within one year</b>	5	(736,303)		(726,522)	
<b>Net current liabilities</b>			(729,088)		(716,632)
<b>Net liabilities</b>			(152,973)		(141,402)
<b>Capital and reserves</b>					
Called up share capital presented as equity			101		101
Profit and loss reserves	6	(153,074)		(141,503)	
<b>Total equity</b>			(152,973)		(141,402)

# JODEL PHARMACY LIMITED

## STATEMENT OF FINANCIAL POSITION (CONTINUED)

**AS AT 31 MARCH 2025**

---

We, as directors of Jodel Pharmacy Limited, state that:

(a) The company is availing itself of the exemption from audit provided for by Chapter 15 of Part 6 of the Companies Act 2014.

(b) The company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied.

(c) The shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2).

(d) The directors acknowledge the obligations of the company, under the Companies Act 2014:


(i) to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a year; and


(ii) to otherwise comply with the provisions of this Act relating to financial statements so far as they are applicable to the company.

(e) The company has relied on the specified exemption contained in section 352 Companies Act 2014; the company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with Financial Reporting Standard 102 'The Financial Statement Reporting Standard applicable in the UK and Republic of Ireland'.

The financial statements were approved by the board of directors and authorised for issue on 8 July 2025 and are signed on its behalf by:

DocuSigned by:  
  
07B02B533E7141A  
Dolores Shanahan  
Director

DocuSigned by:  
  
F830D634695D450...  
John Shanahan  
Director

# JODEL PHARMACY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

### FOR THE YEAR ENDED 31 MARCH 2025

---

#### 1 Accounting policies

##### Company information

Jodel Pharmacy Limited is a limited company domiciled and incorporated in the Republic of Ireland. The registered office is 41 Park View, Deerpark, Castletknock, Dublin 15 and its company registration number is 529404.

#### 1.1 Accounting convention

These financial statements have been prepared on a going concern basis and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102"), as adapted by Section 1A of FRS 102, and the requirements of the Companies Act 2014.

The financial statements are prepared in euros, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest €.

The financial statements have been prepared under the historical cost convention.

#### 1.2 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Land and buildings freehold	No depreciation
Fixtures and fittings	No depreciation

Freehold land and assets in the course of construction are not depreciated.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

#### 1.3 Impairment of fixed assets

Assets not measured at fair value are reviewed for any indication that the asset may be impaired at each balance sheet date. If such indication exists, the recoverable amount of the asset, or the asset's cash generating unit, is estimated and compared to the carrying amount. Where the carrying amount exceeds its recoverable amount, an impairment loss is recognised in profit or loss unless the asset is carried at a revalued amount where the impairment loss is a revaluation decrease.

#### 1.4 Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

#### 1.5 Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

# JODEL PHARMACY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2025

---

#### 1 Accounting policies

(Continued)

##### **Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

##### **Classification of financial liabilities**

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

##### **Basic financial liabilities**

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest.

#### 1.6 Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

#### 1.7 Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

#### 1.8 Foreign exchange

Transactions in currencies other than euros are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

#### 2 Employees

There were no employees during the year other than directors who received no remuneration for their services.

# JODEL PHARMACY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

### 3 Tangible fixed assets

	Land and buildings freehold	Fixtures & fittings	Total
	€	€	€
<b>Cost</b>			
At 1 April 2024	549,447	58,866	608,313
Additions	-	885	885
	<u>549,447</u>	<u>59,751</u>	<u>609,198</u>
At 31 March 2025	549,447	59,751	609,198
	<u>549,447</u>	<u>59,751</u>	<u>609,198</u>
<b>Depreciation and impairment</b>			
At 1 April 2024	-	-	-
Impairment losses	33,083	-	33,083
	<u>33,083</u>	<u>-</u>	<u>33,083</u>
At 31 March 2025	33,083	-	33,083
	<u>33,083</u>	<u>-</u>	<u>33,083</u>
<b>Carrying amount</b>			
At 31 March 2025	516,364	59,751	576,115
	<u>516,364</u>	<u>59,751</u>	<u>576,115</u>
At 31 March 2024	516,364	58,866	575,230
	<u>516,364</u>	<u>58,866</u>	<u>575,230</u>

### 4 Debtors

	2025	2024
	€	€
<b>Amounts falling due within one year:</b>		
Prepayments	4,052	4,052
	<u>4,052</u>	<u>4,052</u>

### 5 Creditors: amounts falling due within one year

	2025	2024
	€	€
Trade creditors	-	508
Amounts owed to group undertakings	736,303	721,484
Accruals	-	4,530
	<u>736,303</u>	<u>726,522</u>
	<u>736,303</u>	<u>726,522</u>

# JODEL PHARMACY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

### 6 Profit and loss reserves

	2025 €	2024 €
At the beginning of the year	(141,503)	(125,064)
Adjusted balance	(141,503)	(125,064)
Loss for the year	(11,571)	(16,439)
At the end of the year	<u>(153,074)</u>	<u>(141,503)</u>

### 7 Events after the reporting date

There have been no significant events which would materially affect the financial statements which require disclosure.

### 8 Related party transactions

#### Transactions with related parties

During the year the company entered into the following transactions with related parties:

As at 31st March 2025 Jodel Pharmacy Limited owed Summerhill Pharmacy Limited €495,515 Cr (2024: €498,196 Cr).

As at 31st March 2025 Jodel Pharmacy Limited owed Scriptus Limited €40,289 Cr (2024: €40,289 Cr)

As at 31st March 2025 Jodel Pharmacy Limited owed N & D Pharmacy Limited €200,500 Cr (2024: €183,000 Cr).

### 9 Parent company

John and Dolores Shanahan have ultimate control of Jodel Pharmacy Limited. They own 100% of the issued share capital.

The 'A' ordinary share is held by N & D Pharmacy Limited, a company in which the directors John and Dolores are 100% shareholders.

### 10 Approval of financial statements

The directors approved the financial statements on 8 July 2025.